ERBB2 and breast cancer: Conversely, according to the literature and consistent with our observations, better prognosis or OS was observed in patients with HER2-positive (HR-negative) BC and BMBC, respectively likely due to the above mentioned systemic treatment possibilities (43, 44, 47, 54)